Abcellera Biologics (ABCL) revenue breakdown
By product, Licensing and royalty revenue is the largest at 62% of fiscal 2025 revenue, growing 23% a year over 4 years.
By region, Canada is the largest at 85% of fiscal 2025 revenue; United States grew fastest, -20% a year over 3 years.
Revenue by product
Fiscal years, as Abcellera Biologics reports them in its 10-K filings; fiscal 2025 total $75M.
| Products | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| Licensing and royalty revenue | — | $21M | $696,000 | $969,000 | $1M | $47M | 62% |
| Research fees | $20M | $19M | $41M | $36M | $26M | $27M | 36% |
| Milestone payments | $15M | $8M | $900,000 | $2M | $2M | $1M | 1% |
| Royalty revenue | — | — | $443M | — | — | — | — |
| Royalty revenue | $198M | $327M | — | — | — | — | — |
Revenue by region
Fiscal years, as Abcellera Biologics reports them in its 10-K filings; fiscal 2025 total $75M.
| Regions | 2021 | 2022 | 2023 | 2025 | Share |
|---|---|---|---|---|---|
| Canada | $353M | $484M | $36M | $64M | 85% |
| United States | $22M | $1M | $2M | $11M | 15% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ABCL.
Open ABCL in InvestinglyQuestions
Where does Abcellera Biologics make its money?
In fiscal 2025, by product: Licensing and royalty revenue $47M, Research fees $27M, Milestone payments $1M.
From Abcellera Biologics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.